A contract believed to account for a significant share of Novo Nordisks volumes in the US has slipped from the grip of the Danish pharmaceutical group and into the hands of fierce rival, Eli Lilly.
The contract in question is with US company Express Scripts, the largest pharmacy benefit management organization in the United States. But Novo Nordisk is reluctant to comment on the lost contract, which has caused its share price to drop by 3 %.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app